Pharmaceutical China New Drug R&D&International-Beletalent

Beletalent(ZHUHAI)Pharmaceutical Co., Ltd（hereinafter referred to as Beletalent），which was founded in 2023, with a registered capital of 20 million RMB and located in Hengqin, Guangdong Province, China, Guangdong-Macau Deep Cooperation Zone, it is a wholly-owned subsidiary of Guizhou Bailing Group Pharmaceutical Co., Ltd (hereinafter referred to as “Guizhou Bailing”).It is a science and technology-based pharmaceutical enterprise specializing in innovative drug research, industrialization and international trade.


Beletalent existing staff of nearly 50 people (including part-time), including 9 senior titles, Dr. 12 people. The R&D pipeline covers the R&D of new drugs of Class 1.1 innovative Chinese medicines and Class 3.1 classic prescriptions; the international trade involves the overseas registration and sales of drugs related to cardiovascular and cerebral vascular diseases, rheumatism and bone pains, purging and detoxification of body heat and bile, liver and gallbladder medicines and respiratory system diseases.


As an integrated unit of “new drug R&D + international trade”, relying on the R&D platforms of Guizhou Bailing National Technical Center and National Engineering Center, first-class experts and technical teams, modern production technology and green manufacturing; at the same time, making full use of the policy and location advantages of Hengqin and Macao, the company focuses on the development of new drug R&D and international trade business, and gradually realizes the goal of ” Anchored in Hengqin and Macao, we gaze upon the whole of China, and aspire to reach out to the world! “